ArticlePLoS genetics2025
Conservation and divergence of ciprofloxacin persister survival mechanisms between Pseudomonas aeruginosa and Escherichia coli.
Article in PLoS genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic analysis of epistasis between nucleotide excision repair and homologous recombination in the recovery of persisters after fluoroquinolone treatment.PLoS genetics · 2026Article
- Contributions of persisters and the Eagle effect to survival ofMicrobiology spectrum · 2026Article
- Non-canonical double-stranded DNA break repair in Pseudomonas aeruginosa includes LigD-independent non-homologous end joining.Nucleic acids research · 2026Article
- Stationary-phasemSphere · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Studies have shown that DNA damage repair systems, including homologous recombination (HR) and the SOS response, are important for fluoroquinolone (FQ) persistence of Escherichia coli, which has been the workhorse organism of persister research. We sought to explore whether those systems are also important for FQ persistence of Pseudomonas aeruginosa, a common cause of lung infections in cystic fibrosis patients, which can be treated with FQs such as ciprofloxacin (CIP). Notably, P. aeruginosa has important differences in its DNA damage repair capabilities compared to E. coli that include the machinery needed to conduct non-homologous end-joining (NHEJ), Ku and LigD. Using a genetic approach, we found that loss of HR significantly depressed persister levels of P. aeruginosa to CIP during stationary-phase, but not in exponential-phase. This differed from E. coli grown in identical conditions, where loss of HR reduced survival in both stationary- and exponential-phase populations. Similarly, an inability to induce the SOS response reduced survival during both growth phases for E. coli but only in stationary-phase for P. aeruginosa. Loss of NHEJ machinery in P. aeruginosa did not impact persister levels during stationary- or exponential-phase, whereas overexpression of NHEJ machinery in P. aeruginosa had toxic effects. In addition, the generality of findings to another FQ, levofloxacin, and a recent clinical isolate, MRSN 1612, were confirmed. These results demonstrate that HR and the SOS response are important to CIP persistence of stationary-phase P. aeruginosa, dispensable to CIP persisters in growing P. aeruginosa cultures, and that the contributions of systems to E. coli persistence do not directly translate to persisters of P. aeruginosa.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.